ArticleMolecular neurobiology2026
Associations of Iron Indicators with Cognitive Impairment Risk in Postmenopausal Women: Evidence from a Matched Case-Control Study and Back Propagation Neural Network Model.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Iron is essential for normal cognitive function, and women have nearly twice the age-matched prevalence of cognitive impairment compared with men. The matched case-control study included 1344 postmenopausal women aged over 60 years, and cognitive status was assessed using Mini-Cog. Plasma ferritin and hepcidin were detected by enzyme-linked immunosorbent assay (ELISA), and total iron binding capacity (TIBC) was determined by colorimetry. Conditional logistic regression and restricted cubic splines (RCS) were used to analyze the relationship between each iron indicator and cognitive impairment risk, with stratified analyses by age and body mass index (BMI) conducted. Additionally, sensitivity analysis was performed to verify the robustness of the results. Back-propagation neural network (BPNN) was utilized as exploratory supplementary tool to quantify the relative importance of multiple factors. The results indicated that elevated hepcidin levels were positively correlated with higher cognitive impairment risk (OR = 1.515, 95% CI: 1.067-2.150). RCS analysis indicated a non-linear association between TIBC and the risk of cognitive impairment (P for nonlinear = 0.002), with exploratory inflection point observed at 100.69 μmol/L. In contrast, ferritin levels showed no statistically significant association with cognitive impairment risk. The BPNN model identified hepcidin (95.5% importance) and TIBC (79.1%) as having relatively high importance, alongside certain blood indicators (albumin, MONO, HDL, TP), listening to the radio and reproductive lifespan. The internal validation of the model AUC reached 0.744. These findings suggested that hepcidin and TIBC were associated with cognitive impairment risk in postmenopausal women, offering evidence for cognitive decline in this population.
Indexed as
Identifiers
42593708What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.